MedTrace Logo

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

NCT02170012 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-03-17

No results posted yet for this study

Summary

The purpose of this study in healthy elderly people is to evaluate safety, toleration and time course of plasma concentration of multiple oral doses of PF-06743649- The pharmacodynamic activity of PF-06743649 will also be assessed.

Conditions

  • Healthy Elderly

Interventions

DRUG

PF-06743649

20 mg tablet once daily dosing for 14 days

DRUG

Placebo

Placebo tablet once daily dosing for 14 days

DRUG

PF-06743649

To be decided dose, tablet once daily dosing for 14 days

DRUG

Placebo

Placebo tablet once daily dosing for 14 days

DRUG

PF-06743649

To be decided dose, tablet once daily dosing for 14 days

DRUG

Placebo

Placebo tablet once daily dosing for 14 days

DRUG

PF-06743649

To be decided dose, tablet once daily dosing for 14 days

DRUG

Placebo

Placebo tablet once daily dosing for 14 days

DRUG

PF-06743649

To be decided dose, tablet once daily dosing for 14 days

DRUG

Placebo

Placebo tablet once daily dosing for 14 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02170012 on ClinicalTrials.gov